Drug
Zolbetuximab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Group | anti-claudin 18.2 mAb |
| Mechanism of Action | Anti-Claudin 18.2 antibody |
| Half-life | 7,6-15,2 d |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No DNA-level radiosensitization (ADCC/CDC-mediated) (Saviano et al., Nature Reviews Cancer, 2026; Xie et al., Journal of Hematology & Oncology, 2026). Theoretically, there is no mechanistic basis for increased in-field adverse events; the dominant class adverse effect is GI (nausea/vomiting) from the antibody, independent of RT.
Data on this page refer exclusively to patients treated with
Zolbetuximab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
anti-claudin 18.2 mAb group page.